Anemia in Chronic Kidney Disease: Treating the Numbers, Not the Patients

No abstract is available for this paper.

• Publication year

  2014

• Venue

  JAMA Internal Medicine

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/JAMAINTERNMED.2013.13305
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial

  2012cited by this paper
• A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

  2009cited by this paper
• Use of epoetin in chronic renal failure.

  2007cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006cited by this paper
• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

  1998cited by this paper

• Prostaglandin E2 induced cardiac hypertrophy through EP2 receptor‐dependent activation of β‐catenin in 5/6 nephrectomy rats

  2021cites this paper
• Role of Artificial Intelligence in Kidney Disease

  2020cites this paper
• Recipient's effects on stored red blood cell performance: the case of uremic plasma

  2019cites this paper
• Acute and Chronic Renal Insufficiency in the Total Joint Arthroplasty Patient

  2019cites this paper
• Complications of Kidney Disease.

  2018cites this paper
• Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients

  2017cites this paper
• Renal and Gastrointestinal Considerations in Joint Replacement Surgery.

  2015cites this paper
• Prioritizing Patient‐Centered Care Implementation and Research for Patients with Kidney Disease

  2015cites this paper
• Perioperative Management of Renal Failure and Renal Transplant

  year unknowncites this paper